The MC is too low for what has been delivered and what is in the pipeline for March and the second quarter. EYES stock in US went up 10 fold on the back of one FDA approval and they truly deserved it thanks to their cutting edge medical tech.
Bard had a fast run last month, but with each positive announcement that covers the milestones in their pipeline/portfolio of screening tests, they could have been near the $8 figure in a more sustained way. In the end the MC is not where it should be right now, but it will be when Bard gets the MSM coverage it deserves.
Chart Thread, page-773
-
- There are more pages in this discussion • 720 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
-0.005(0.86%) |
Mkt cap ! $63.40M | |||
| Open | High | Low | Value | Volume |
| 58.0¢ | 58.0¢ | 56.0¢ | $53.11K | 91.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8400 | 56.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.0¢ | 33187 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |